Using cryo-electron microscopy and site-specific mass spectrometry, researchers have mapped the glycans that shield HIV from the immune system.
List view / Grid view
Filter the results
In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
Researchers have shown that factoring in valency to vaccine design can improve the number of antibody binding sites on an antigen.
The team used cryogenic electron microscopy (cryo-EM) to show how the 10E8 antibody interacts with the HIV’s fusion protein to neutralise the virus.
After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
A vaccine adjuvant named 3M-052 was able to provide rhesus monkeys with protection against HIV for over a year, a new study reports.
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
A study has shown that the COVID-19 pandemic has resulted in a high level of research donations, making the condition the third most funded disease on average by year.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
Researchers have used virtual reality (VR) to control how drugs bind to their protein targets, which they say could be useful for designing new treatments.
A group of researchers, led by Professor Zucai Suo, have revealed the mode of action of two HIV drugs and identified how resistance can develop, which they say could lead to improved drug design in the future.
According to a new study, apolipoprotein A-I binding protein restricts HIV-1 replication by targeting lipid rafts and reducing virus-cell fusion.